The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis

Anti-Cancer Drugs

Volumn 10, Issue 1, 1999, Pages 47-54

  Hasinoff, Brian B ^a   Chee, Gaik Lean ^a   Thampatty, Padmakumari ^b   Allan, William P ^b   Yalowich, Jack C ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bisdioxopiperazine; Camptothecin; CHO; Cytotoxicity; Dexrazoxane; DNA; ICRF 187; Topoisomerase II

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ENZYME INHIBITOR; RAZOXANE;

ANIMAL CELL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL;

EID: 0033025348     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199901000-00007     Document Type: Article

References (37)

1. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15: 1318-32.
2. Swain SM, Whaley F, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J clin Oncol 1997; 15: 1333-40.
3. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998; 5: 1-28.
4. Huang Z-X, May PM, Quinlan KM, Williams DR, Creighton AM. Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF-159 and its inactive homologue ICRF-192. Agents Actions 1982; 12: 536-42.
5. Buss JL, Hasinoff BB. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 1993; 40: 86-95.
6. Hasinoff BB. NADPH-cytochrome-P450 reductase promotes hydroxyl radical production by the iron complex of ADR-925, the hydrolysis product of ICRF-187 (dexrazoxane). Free Rad Res 1995; 22: 319-25.
7. Creighton AM, Hellmann K, Whitecross S. Antitumour activity in a series of bisdiketopiperazines. Nature 1969; 22: 384-5.
8. Witiak DT, Wei Y. Dioxopiperazines: chemistry and biology. In: Jucker E, ed. Progress In drug research. Basel: Birkhauser Verlag 1991; 35: 249-363.
9. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991; 51: 4903-8.
10. Ishida R, Miki T, Narita T, et al. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991; 51: 4909-16.
11. Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 1995; 50: 953-8.
12. Hasinoff BB, Yalowich JC, Ling Y, Buss JL. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anti-Cancer Drugs 1996; 7: 558-67.
13. Hasinoff BB, Kuschak TI, Fattman CL, Yalowich JC. The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese Hamster Ovary cells or the catalytic activity of DNA topoisomerase II. Anti-Cancer Drugs 1998; 9: 465-71.
14. Corbett AH, Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 1993; 6: 585-97.
15. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994; 34: 191-218.
16. Gupta M, Fujimori A, Pommier Y. Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1995; 1262: 1-14.
17. D'Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 1989; 989: 163-77.
18. Glisson BS, Ross WE. DNA topoisomerase II: a primer on the enzyme and its unique rote as a multidrug target in cancer chemotherapy. Pharmacol Ther 1987; 32: 89-106.
19. Schested M, Jensen PB, Sorensen BS, Holm B, Friche E, Demant EJF. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 1993; 46: 389-93.
20. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 1994; 91: 1781-5.
21. Synold T, Spencer M, Doroshow J. Dexrazoxane (DX) potentiates the cytotoxic activity of topotecan (T) in a sequence and schedule dependent manner. Proc Am Ass Cancer Res 1997; 38: 322 (abstr 2161).
22. Whitacre CM, Zborowska E, Gordon NH, Mackay W, Berger NA. Topotecan increases topoisomerase Ha levels and sensitivity to treatment with etoposide in schedule-dependent treatment. Cancer Res 1997; 57: 1425-8.
23. Nitiss JL, Rose A, Sykes KC, Harris J, Zhou J. Using yeast to understand drugs that target topoisomerases. Ann NY Acad Sci 1996; 803: 32-43.
24. Pommier Y, Letcurtre F, Fesen MR, et al. Cellular determinants of sensitivity and resistance to DNA Topoisomerase inhibitors. Cancer Invest 1994; 12: 530-42.
25. Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV, Yalowich JC. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukemia K562 cells. Br J Cancer 1994; 69: 687-97.
26. Hasinoff BB, Kuschak TI, Creighton AM, et al. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol 1997; 53: 1843-53.
27. Holm C, Covey JM, Kerrigan D, Pommier Y. Differential requirement of DNA replication for the cytotoxicity DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989; 49: 6365-8.
28. Hsiang Y-H, Lihou MG, Liu LF. Arrest of replication forks by drug stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-82.
29. D'Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 1990; 50: 6919-24.
30. Kizaki H, Onishi Y. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells. Adv Enz Reg 1997; 37: 403-23.
31. Kaufmann SH. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 1991; 51: 1129-36.
32. Bertrand R, O'Connor PM, Kerrigan D, Pommier Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 1992; 28A: 743-8.
33. Creighton AM, Birnie GD. Biochemical studies on growth-inhibitory bisdioxopiperazines. I. Effect on DNA, RNA and protein synthesis in mouse-embryo fibroblasts. Int J Cancer 1970; 5: 47-54.
34. Hallowes RC, West DC, Hellmann K. Cumulative cytostatic effect of ICRF-159. Nature 1974; 247: 487-90.
35. Law JS, Ingher DE, Sartorelli AC. Enhancement of experimental lung metastases by B16 melanoma cells treated with (±)-1,2-bis(3,5-dioxopiperazin-1-yl)propane (ICRF-159). Cancer Res 1978; 38: 2263-70.
36. Ishida R, Sato M, Narita T, et al. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J Cell Biol 1994; 126: 1341-51.
37. Hochster H, Liebes L, Wadler S, et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 1992; 84: 1725-30.